Enveric Biosciences, Inc., a pharmaceutical company, is dedicated to developing various cannabinoid drugs for the treatment of cancer. The company is headquartered in Naples, Florida.
| Revenue (TTM) | $35.41M |
| Gross Profit (TTM) | $8.15M |
| EBITDA | $-8.06M |
| Operating Margin | 0.00% |
| Return on Equity | -183.10% |
| Return on Assets | -96.70% |
| Revenue/Share (TTM) | $37.68 |
| Book Value | $3.94 |
| Price-to-Book | 1.61 |
| Price-to-Sales (TTM) | 0.08 |
| EV/Revenue | 1.758 |
| EV/EBITDA | 0.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -7.30% |
| Shares Outstanding | $3.68M |
| Float | $3.61M |
| % Insiders | 2.15% |
| % Institutions | 4.05% |
Volatility is currently expanding